【广州4月10日电】（记者 叶青 通讯员 张蓝溪）广东省人民医院在乳腺癌诊疗领域取得重大突破，由乳腺肿瘤科王坤教授领导的科研团队成功研发出一款创新的人工智能系统，该系统能够无创性地早期预测乳腺癌患者在接受新辅助化疗后残余肿瘤的负荷。这一突破性的研究成果已被国际知名医学期刊《外科学年鉴》正式收录，彰显了中国在医疗人工智能领域的领先地位。
据广东省人民医院透露，该人工智能系统通过精密的算法分析，能在乳腺癌患者开始新辅助化疗后，准确评估治疗效果，为临床医生提供及时、精准的决策依据。新辅助化疗是指在手术前对肿瘤进行的化疗，以期缩小肿瘤体积，提高手术成功率。而王坤教授团队的这一创新，有望改变传统依赖手术评估疗效的方式，减少患者的手术创伤，提高治疗效率。
王坤教授表示，这一系统的研发，旨在利用科技手段提升乳腺癌诊疗的精准度和人性化，为患者提供更个性化、更有效的治疗方案。该成果的国际认可，标志着中国在医疗人工智能与肿瘤精准医疗的交叉领域取得了重要进展，对全球乳腺癌治疗有着深远影响。
未来，广东省人民医院计划进一步推广这一人工智能系统，以期在全球范围内提升乳腺癌的诊疗水平，减轻患者痛苦，改善生存质量。同时，这也为我国医疗科技的创新与发展树立了新的标杆，推动中国医疗人工智能技术在国际舞台上发挥更大的影响力。
英语如下：
**News Title:** “Guangdong Develops Non-Invasive AI System for Accurate Prediction of Breast Cancer Neoadjuvant Therapy Outcomes”
**Keywords:** AI Predicts Breast Cancer, Neoadjuvant Therapy, Non-Invasive System
**News Content:**
**Guangzhou, April 10** (Reporter Ye Qing, Correspondent Zhang Lanxiu) The Guangdong Provincial People’s Hospital has made a significant breakthrough in breast cancer treatment. A research team led by Professor Wang Kun from the Breast Tumor Department has successfully developed an innovative artificial intelligence (AI) system capable of non-invasively predicting residual tumor burden in breast cancer patients after neoadjuvant chemotherapy. This groundbreaking achievement has been officially published in the renowned medical journal *Annals of Surgery*, highlighting China’s leading position in the field of medical AI.
According to the Guangdong Provincial People’s Hospital, the AI system employs sophisticated algorithms to accurately assess the effectiveness of neoadjuvant chemotherapy in breast cancer patients, providing timely and precise decision-making support for clinicians. Neoadjuvant chemotherapy refers to chemotherapy administered before surgery to reduce tumor size and enhance the likelihood of successful surgery. Professor Wang Kun’s team’s innovation has the potential to transform the traditional reliance on surgery for treatment evaluation, minimizing surgical trauma for patients and enhancing treatment efficiency.
Professor Wang Kun stated that the development of this system aims to leverage technology to increase the precision and humanization of breast cancer treatment, offering more personalized and effective treatment options for patients. The international recognition of this achievement signifies a significant advancement in the intersection of medical AI and precision oncology in China, with far-reaching implications for global breast cancer treatment.
In the future, the Guangdong Provincial People’s Hospital intends to expand the use of this AI system globally, aiming to enhance breast cancer diagnosis and treatment standards, alleviate patient suffering, and improve quality of life. This milestone also sets a new benchmark for innovation and development in China’s medical technology, propelling Chinese medical AI technology to exert greater influence on the international stage.
【来源】http://www.chinanews.com/life/2024/04-11/10196599.shtml
Views: 3